Direct answer
For established atopic dermatitis, regular unperfumed moisturizer and prescribed anti-inflammatory treatment form the core plan; other eczema types need care matched to their cause. Bathing and clinician-supervised wet wraps have conditional guideline support. Preventing a first diagnosis is a separate question: pediatric moisturizer prevention is conditional, while probiotics and vitamin D are not recommended specifically for that purpose. Supplement treatment evidence is uncertain, and correcting a nutritional deficiency does not establish a proven eczema benefit.
- A 2017 Cochrane review included 77 moisturizer studies with 6,603 participants. Its flare analysis used six studies and 607 participants: moisturizer groups had lower flare risk than vehicle, placebo or no moisturizer (RR 0.33, 95% CI 0.17–0.62; moderate-certainty evidence). This concerns established atopic eczema, not prevention of a first diagnosis; 46 trials reported funding, mostly from industry. Cochrane review
- Cochrane found no reliable evidence that any one moisturizer ingredient beats another — a practical choice is an unperfumed product the person tolerates and can use regularly.
- AAD’s pediatric guideline conditionally recommends against probiotic or vitamin D supplementation to prevent a first diagnosis of atopic dermatitis. This is distinct from treatment of established disease.
- About 70% of people with atopic dermatitis have a blood relative with atopic dermatitis, asthma, or hay fever, underscoring that genetics plus barrier weakness — not one trigger — usually drives flares (AAD causes page).
- Broad food-elimination diets rarely stop atopic dermatitis and can cause poor growth, nutrient deficiency, and protein malnutrition in children — AAD advises considering food allergy testing when moderate-to-severe eczema remains uncontrolled despite skin care and medicines, or when an immediate reaction follows a specific food.
Skin barrier health · Eczema · Evidence-based guide
Eczema includes several conditions with different causes and treatment priorities. For atopic dermatitis, the core plan is regular unperfumed moisturization and prescribed anti-inflammatory treatment, with attention to individual triggers. Bathing and wet wraps are conditional options, with wraps supervised by a trained clinician. Supplement findings are weaker or uncertain: vitamin D reviews conflict, omega-3 trials are preliminary, and the reviews cited here do not support routine probiotic or evening primrose/borage treatment (AAD guideline, Cochrane emollients review, Cochrane probiotics review, Cochrane evening primrose/borage review).
Table of contents
- Evidence summary
- What eczema is
- Types of eczema
- How eczema works: the flare loop
- Triggers: irritants, allergens, stress, climate, sweat, and infection
- Prevention: what reduces flares
- Management: what to do during a flare
- Supplements for eczema
- What works and what does not
- Selected risks and side effects
- Selected interactions and precautions
- Who should avoid or seek medical care first
- FAQ
- Sources
Evidence summary
| Claim | Evidence | Source country / scope | Funding / conflict trace | Strength |
|---|---|---|---|---|
| Daily moisturizers reduce eczema flares and support treatment. | The review included 77 studies and 6,603 participants; the flare estimate came from six studies and 607 participants (RR 0.33, 95% CI 0.17–0.62; moderate certainty). Some trials also found lower topical corticosteroid use. | International trials; Cochrane review. | 46 trials reported funding, mostly from industry. Evidence certainty varied by endpoint; downgrades concerned bias, inconsistency, imprecision and indirectness, rather than sponsorship alone. Full review | WORKS Cochrane |
| No one moisturizer ingredient is clearly best for everyone. | Cochrane concluded most moisturizers help but found no reliable evidence that one moisturizer is superior to another. | International trials; Cochrane review. | Many trials reported product-company funding or manufacturer-employed investigators; other trial finances were unreported. | Strong practical verdict Cochrane |
| Topical corticosteroids and topical calcineurin inhibitors are core anti-inflammatory treatments. | AAD gives strong recommendations for topical corticosteroids and topical calcineurin inhibitors in adult and pediatric atopic dermatitis. | United States guideline, globally relevant principles. | The original 2023 adult guideline reported internal AAD funding and workgroup industry relationships with recusal procedures. The 2026 pediatric publisher record also reports internal AAD funding; its complete workgroup declarations were not recovered. | WORKS AAD |
| Bathing and wet wrap therapy can help selected patients but are not one-size-fits-all. | AAD conditionally recommends bathing and wet wrap therapy; a 50-child RCT found both wet wraps and conventional therapy improved SCORAD but did not prove superiority of wet wraps at four weeks. | Guideline plus pediatric RCT. | Hindley’s trial was NHS North West-funded; authors declared no competing interests, but product-supply terms were not stated. AAD guideline financing is discussed below. Hindley 2006 | MIXED / targeted use AAD / RCT |
| Routine probiotic treatment does not meaningfully improve established eczema for most people. | Cochrane reviewed 39 RCTs with 2,599 participants and found probiotics probably make little or no difference to patient-rated eczema symptoms. | International trials; Cochrane review. | The review reported institutional/NIHR support and author links to Danone and other infant-nutrition/probiotic companies, including Prota employment/share interests. Ten trials had supplier funding and four did not declare funding. Full review | DOESN’T as routine treatment Cochrane |
| Vitamin D may modestly reduce eczema severity in some people, but prevention evidence is not strong enough for routine use. | A 2024 meta-analysis of 11 RCTs and 686 participants found reduced severity (SMD −0.41), while a 2023 meta-analysis of 5 RCTs found no general effect and subgroup uncertainty. | International RCTs and reviews. | 2024 review reported no external funding but disclosed dermatology/pharma relationships for two authors; 2023 review had public Korean funding and no conflicts. | MIXED / targeted 2024 meta-analysis / 2023 meta-analysis |
| Omega-3 evidence is promising but not settled. | A small four-week pediatric EPA trial reported improvement alongside standard topical care. The older Cochrane review found no convincing routine supplement benefit; small fish-oil signals were uncertain. | Iran pediatric RCT; international Cochrane review. | EPA authors declared no specific grant or financial conflicts; Epastigel/Pars Pharmed capsules were identified, but purchase/donation terms were not reported. The Cochrane review listed University of Nottingham support, no external support and no known interests; some underlying finances remain unclear. | MIXED / promising EPA RCT / Cochrane |
| Evening primrose oil and borage oil should not be recommended for eczema treatment. | Cochrane reviewed 27 studies with 1,596 participants and found no statistically significant advantage over placebo. | 12-country evidence base; Cochrane review. | The full review lists internal support, no external support and author trial-related interests, including an Efamol-funded/supplied trial. Underlying-study financial chains were not exhaustively traced. Full review | DOESN’T Cochrane |
What eczema is
Eczema is a family of inflammatory skin conditions that cause irritated, dry, itchy, sometimes painful skin; atopic dermatitis is the most common type, but contact dermatitis, stasis dermatitis, dyshidrotic eczema, nummular eczema, hand eczema, seborrheic dermatitis, and neurodermatitis can all sit under the wider eczema/dermatitis umbrella (AAD Eczema Resource Center, AAD atopic dermatitis overview). Atopic dermatitis is not contagious and often begins in childhood, but eczema can begin or persist into adulthood (AAD atopic dermatitis overview, AAD adult eczema).
The practical definition matters: if the rash is mainly a barrier-and-inflammation disease, daily prevention matters even when the skin looks clear; if it is contact dermatitis, identifying the irritant or allergen matters; if it is stasis dermatitis, circulation and leg swelling must be addressed; and if it is seborrheic dermatitis, yeast-associated oily-area inflammation often requires a different plan (AAD contact dermatitis, AAD stasis dermatitis, AAD seborrheic dermatitis treatment).
Text version of this infographic
Eczema is a family of conditions that share inflamed, itchy, barrier-disrupted skin. Main forms include atopic dermatitis, contact dermatitis, hand eczema, dyshidrotic eczema, nummular eczema, stasis dermatitis, seborrheic dermatitis, and neurodermatitis. Identifying the type matters because triggers and treatment priorities differ.
Types of eczema
| Type | Typical pattern | Common drivers or triggers | First management emphasis | Verdict |
|---|---|---|---|---|
| Atopic dermatitis | Chronic, itchy, dry, inflamed skin; often begins early in life but can start at any age. | Barrier weakness, genes, immune activation, dry air, irritants, fragrances, sweat, stress, microbes, and sometimes allergens. | Daily moisturizer, trigger management, anti-inflammatory treatment for flares. | Most common eczema type AAD |
| Contact dermatitis | Rash after something touches skin; can be irritant or allergic. | Soaps, detergents, solvents, plants, metals, fragrances, gloves, topical products. | Find and avoid the irritant/allergen; treat inflammation. | Trigger-identification disease AAD |
| Hand eczema | Dry, thick, scaly hands; cracks, bleeding, burning, blisters, or weeping. | Wet work, water, detergents, solvents, cement, latex, occupational exposure, history of atopic dermatitis. | Glove strategy, barrier repair, avoiding repeated wet/chemical exposure. | High recurrence unless exposures change AAD |
| Dyshidrotic eczema | Tiny intensely itchy blisters on hands or feet; may recur seasonally. | Nickel/cobalt sensitivity, personal-care ingredients, stress, sweating, temperature changes, wet hands, cutting oil or cement exposure. | Identify hypersensitivity, protect hands/feet, manage sweat and irritation. | Blistering hand/foot subtype AAD |
| Nummular eczema | Round or oval itchy plaques, often on hands, forearms, or lower legs. | Very dry skin, skin injury, stress, certain medicines and contact hypersensitivity. | Treat dry skin and plaques early; a dermatologist can distinguish this from ringworm or psoriasis and assess contact allergy. | Coin-shaped eczema AAD |
| Stasis dermatitis | Eczema near ankles/lower legs from poor blood flow; also called venous or varicose eczema. | Venous insufficiency, swelling, skin fragility, poor lower-leg circulation. | Manage swelling/circulation plus skin inflammation; rule out ulcers/infection. | Circulation-linked eczema AAD |
| Seborrheic dermatitis | Scaly rash on oily areas such as scalp, face, eyebrows, ears, chest, and skin folds. | Yeast-associated inflammation, oily areas, neurologic/immunologic risk in some people. | Age-appropriate dandruff or antifungal treatment and anti-inflammatory care when prescribed; infant cradle cap needs a different plan. | Different mechanism than classic dry AD AAD |
| Neurodermatitis | One or two intensely itchy thickened patches from the itch-scratch cycle. | Stress, anxiety, repeated scratching/rubbing, sleep-time itch. | Stop the itch-scratch loop; treat inflammation and behavior trigger. | Itch-scratch-cycle eczema AAD |
How eczema works: the flare loop
Atopic dermatitis often starts with a leaky skin barrier: gaps in the stratum corneum let water escape, allow irritants such as fragrances or dust-mite particles to enter, and make it easier for viruses and bacteria to aggravate inflamed skin (AAD causes page). Genetics, immune overactivity, and what touches the skin interact; AAD notes that about 70% of people with atopic dermatitis have one or more blood relatives with atopic dermatitis or an allergic disease such as asthma or hay fever (AAD causes page).
Original insight: eczema control usually fails when people treat only one part of the loop. A moisturizer repairs water loss but does not fully calm immune inflammation; a steroid calms inflammation but does not replace daily barrier care; trigger avoidance helps but rarely replaces treatment once a flare is active (AAD guideline, AAD food guidance).
Text version of this infographic
- Barrier leak: water escapes and irritants enter.
- Triggers such as soap, sweat, stress, dry air, allergens, or infection worsen the barrier.
- Inflammation causes redness, swelling, and itch.
- Scratching causes micro-injury and increases infection risk.
- The loop is broken by moisturization, trigger avoidance, anti-inflammatory treatment, and sleep/itch control.
Triggers: irritants, allergens, stress, climate, sweat, and infection
Eczema triggers are individual, but AAD lists dry air, sudden temperature change, laundry detergent, baby wipes, stress, heat, sweat, and pool water as common flare drivers in children, while AAD severe-AD guidance also names dry air, sweat, and stress as common aggravators (AAD triggers, AAD severe AD). A 2016 narrative review of environmental risk factors found plausible roles for soaps/detergents, sodium lauryl sulfate irritancy, fragrances, nickel/rubber/fragrance exposures, climate, humidity, pollution, tobacco smoke, and stress, with funding from AHRQ and the Dermatology Foundation and no relevant author financial conflicts reported (Environmental risk factors review).
Allergens require precision. AAD states that in most cases atopic dermatitis is not caused or triggered by one specific allergy, even though food allergies, hay fever, or asthma may develop in many people with atopic dermatitis (AAD causes page). Food testing is most appropriate when moderate-to-severe atopic dermatitis remains uncontrolled despite skin care and medicine or when an immediate reaction follows a specific food; broad elimination diets can cause poor growth, nutrient deficiencies, and protein malnutrition in children (AAD food guidance).
| Trigger class | Examples | How to test it safely | What not to do |
|---|---|---|---|
| Irritants | Fragrance, harsh soap, detergents, wipes, solvents, cement, repeated water exposure. | A practical diary can track product changes, exposure, itching and cracks; discuss persistent or reproducible reactions with a clinician. | Do not keep adding botanical oils or “natural” fragranced products; fragrance can still irritate eczema-prone skin. |
| Allergens | Nickel, cobalt, rubber/latex, fragrance allergens, dust mites, animal dander, pollen, mold in selected people. | Use history and clinician-directed patch or allergy testing when patterns fit. | Do not assume a positive IgE or skin test proves the allergen caused every flare. |
| Climate | Dry air, low humidity, heat, sweat, cold-to-warm transitions, seasonal changes. | Track flares against humidity, temperature, exercise, bedding, and bathing. | Do not over-bathe with hot water or leave skin unmoisturized after water exposure. |
| Stress and sleep | Exam stress, work stress, anxiety, bedtime scratching, sleep loss. | Track flare intensity against stressful weeks and nighttime scratching. | Do not frame stress as “all in your head”; stress can worsen itch biology and scratching behavior. |
| Infection | Weeping, crusting, pain, rapidly worsening redness, fever, pustules, herpes-like blisters. | Seek medical care, especially for painful or spreading lesions. | Do not cover a suspected infection with occlusive wet wraps without medical guidance. |
Prevention: what reduces flares
Preventing flares in established atopic dermatitis differs from preventing a first diagnosis. For primary prevention, AAD’s 2026 pediatric guideline conditionally supports moisturizing skin care; its announcement identifies children aged six months to three years. It conditionally recommends against probiotic or vitamin D supplementation specifically for primary AD prevention. These recommendations do not replace nutritional care or prove moisturizer prevention for every age and eczema type (AAD guideline, AAD pediatric guideline announcement).
Moisturization protocol
Use a bland, fragrance-free moisturizer as the anchor habit. Cochrane found moisturizers prolong time to flare, reduce flare number, reduce the amount of topical corticosteroid needed in some studies, and work better when combined with active treatment than active treatment alone (Cochrane emollients review). NICE advises unperfumed emollients for children with atopic eczema and says emollients are the basis of management and should continue even when eczema is clear (NICE recommendations).
| Moisturizer form | Practical fit | Pros | Cons / side effects | Verdict |
|---|---|---|---|---|
| Ointment / balm | Very dry, cracked, thickened, or winter-flaring skin. | Most occlusive; reduces water loss. | Greasy feel; can trap heat; folliculitis in some people. | Occlusive option |
| Cream | Daily body use for most people. | Good balance of hydration and acceptability. | Some preservatives or botanicals can sting or irritate. | Acceptability option |
| Lotion | Hair-bearing areas or hot/humid settings when thicker products are intolerable. | Spreads easily. | Less occlusive; individual formulations may sting or irritate. | Acceptability option |
| Humectant-rich products | Dry but not fissured skin; maintenance. | Glycerin/urea/lactic acid can draw water into stratum corneum. | Urea/lactic acid can sting active eczema; urea had more adverse events in one Cochrane comparison. | Discuss tolerance; change if irritating. Cochrane |
| Colloidal oat products | Some itch-prone skin; preference-based use. | Can feel soothing. | Cochrane found no clear superiority for several oat comparisons and possible higher adverse events in one study. | Optional, not magic Cochrane |
Bathing without making eczema worse
Bathing can hydrate skin and remove scale, crust, allergens, irritants, and microbes, but evaporation after bathing can worsen dryness if moisturizer is not applied promptly; AAD conditionally recommends bathing, and AAD public guidance emphasizes baths plus moisturizers as part of eczema control (AAD guideline, AAD food guidance). AAD finds insufficient evidence for one optimal bathing frequency, temperature or duration. A practical plan uses gentle washing and prompt moisturizer; NICE advises emollient soap substitutes for children under 12 and does not recommend separately marketed emollient bath additives. Emollient residue on clothes/bedding can create a fire hazard, so keep these materials away from flames and smoking. NICE guidance
Text version of this infographic
- The foundation is daily fragrance-free moisturizer.
- The second layer is gentle bathing followed by sealing damp skin with moisturizer.
- The third layer is a trigger diary and targeted exposure reduction.
- The fourth layer is early anti-inflammatory treatment for flares.
- Supplement benefit for eczema is uncertain; assess nutritional or other indications separately and keep the prescribed skin-care plan.
Management: what to do during a flare
The flare rule is simple: hydrate the barrier and calm inflammation early. AAD strongly recommends moisturizers and several prescribed topical anti-inflammatory treatments for adult and pediatric atopic dermatitis, with product- and age-specific eligibility. Bathing and wet wraps receive conditional support. Adult guidance conditionally recommends against routine topical antimicrobials, antiseptics and antihistamines; pediatric guidance conditionally supports clinician-selected bleach baths, so adult recommendations should not be generalized to every child (AAD guideline).
| Management layer | What it does | Best use | Main caution | Evidence verdict |
|---|---|---|---|---|
| Emollients / moisturizers | Reduce water loss and support barrier repair. | Daily prevention and during every flare. | Choose fragrance-free; stop products that sting, burn, or worsen redness. | Core Cochrane |
| Topical corticosteroids | Rapidly reduce inflammatory flare activity. | Flare courses and, for recurrent disease, intermittent maintenance matched to site, age, severity and clinician plan. | High potency, large-area use, occlusion, thin skin, and long duration increase side-effect risk. | Core flare medicine AAD |
| Topical calcineurin inhibitors | Reduce immune inflammation without steroid skin-thinning. | Sensitive areas, frequent flares, or steroid-sparing maintenance when prescribed. | Early burning/stinging can occur. Eligibility is product- and age-specific; these agents are not a routine option for immunocompromised patients. | Useful steroid-sparing option Review |
| Topical PDE-4 inhibitors, including crisaborole | Reduce inflammatory signaling. | Mild-to-moderate eczema when prescribed. | Application-site pain/burning can occur. | Works for selected patients Review |
| Topical ruxolitinib (JAK inhibitor) | Target cytokine signaling involved in itch/inflammation. | US label: non-immunocompromised patients aged two or older with mild-to-moderate AD inadequately controlled by other prescribed topicals, or when those therapies are inadvisable. | Use within labeled area/quantity limits and without occlusive dressings. Combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants is not recommended; review boxed warnings and other medicines. FDA label | Medical option AAD |
| Wet wrap therapy | Occludes moisturizer/medicine, cools itch, protects from scratching. | Short-term moderate-to-severe flares under guidance. | Increases topical steroid absorption and may worsen infection risk if done incorrectly. | Targeted rescue layer RCT |
| Phototherapy/systemic medicines | Reduce widespread or severe disease activity. | Moderate-to-severe eczema not controlled with topical care. | Specialist selection by age and disease severity, with product-specific screening and monitoring; AAD strongly recommends against routine systemic corticosteroids for AD. | Specialist layer AAD |
Wet wrap therapy: where it fits
Wet wrap therapy combines moisturizer or prescribed treatment with a damp layer covered by a dry layer. AAD conditionally recommends it for selected cases. Hindley’s four-week pediatric maintenance trial found no significant advantage over supported conventional care; antibiotic-treated skin infections occurred in 5/23 wet-wrap participants versus 0/22 controls. That intensive regimen should not be equated with short-term, clinician-guided rescue use (AAD guideline, Hindley wet-wrap RCT).
Do not use wet wraps over suspected infection, rapidly spreading rash, painful blisters, or undiagnosed weeping/crusting lesions unless a clinician has assessed the skin. Occlusion increases topical corticosteroid absorption, and NCBI Bookshelf lists occlusive dressings, inflamed skin, large treated areas, high-potency steroids, prolonged use, thin skin, and pediatric body-surface ratio as factors that increase topical corticosteroid exposure (Topical Corticosteroids—NCBI Bookshelf).
Text version of this infographic
Flare action flow: first check for red flags such as pain, fever, pus, spreading redness, or herpes-like blisters; moisturize liberally; use the prescribed anti-inflammatory treatment; reduce scratching with sleepwear, nail care, and clinician-guided wraps when appropriate; identify the likely trigger; escalate care if the flare does not improve or infection is suspected.
Supplements for eczema
Supplements should be considered only after the barrier plan is in place. AAD states that supplement therapies such as probiotic or vitamin D supplementation are not proven for pediatric atopic dermatitis prevention, and AAD food guidance states that when studies are reviewed overall there is little evidence to support specific foods or supplements as eczema fixes (AAD guideline, AAD food guidance).
| Supplement | Evidence for eczema | Possible role | Key safety issues | Verdict |
|---|---|---|---|---|
| Vitamin D | 2024 meta-analysis found modest reduction in severity across 11 RCTs; 2023 meta-analysis found no general effect and high subgroup uncertainty. | Correct deficiency when clinically indicated, but pooled eczema trials do not establish that low baseline vitamin D reliably predicts a better eczema response. | Excess can cause hypercalcemia, kidney stones, vomiting, weakness, confusion, arrhythmia, renal failure; interacts with thiazides, orlistat, corticosteroids, and some statins. | MIXED / targeted Meta-analysis / NIH ODS |
| Omega-3 EPA/DHA | A small adjunct EPA trial and a four-month pediatric blend trial reported benefits. The blend contained EPA, DHA, GLA and vitamin D3; its result cannot be attributed to fish oil alone. The older Cochrane review did not establish routine supplement benefit. Blend trial | Discuss nutritional or other indications separately; eczema benefit remains preliminary. | Fishy taste, reflux, nausea, diarrhea, headache; high doses may prolong bleeding time and 4 g/day trials found slightly higher atrial fibrillation risk in high-risk cardiovascular populations. | MIXED / promising EPA RCT / NIH ODS |
| Probiotics | Cochrane found little or no benefit for established eczema; NCCIH notes inconsistent pediatric treatment evidence and preliminary adult strain-specific evidence. | Not a routine eczema treatment; strain selection matters if used. | GI upset; rare serious infection risk in premature infants, severely ill, or immunocompromised people; product contamination/mislabelling concerns. | DOESN'T routinely Cochrane / NCCIH |
| Evening primrose oil / borage oil | Cochrane found no significant benefit across 27 studies. | No evidence-based routine role for eczema. | GI upset, headache, diarrhea; evening primrose oil may increase bleeding risk with warfarin in some reports; long-term safety not established. | DOESN'T Cochrane / NCCIH |
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|---|---|---|
| “Moisturizer prevents flares.” | WORKS | Cochrane found fewer flares and longer time to flare with moisturizers. | Choose a tolerable product that can be used regularly; the review does not rank adherence against ingredients in a randomized comparison. Many trials had product-company ties. Cochrane |
| “A specific moisturizer ingredient is always best.” | DOESN'T | Cochrane found no reliable evidence that one moisturizer is best. | Choose a product the person will use daily without irritation. Cochrane |
| “Topical corticosteroids are unsafe and should be avoided.” | DOESN'T | AAD strongly recommends them; safety risk rises with potency, duration, occlusion, large area, and thin skin. | Fear-driven undertreatment can prolong flares; misuse can cause side effects. AAD / NCBI Bookshelf |
| “Wet wraps are a universal cure.” | MIXED | AAD conditionally recommends; RCT evidence does not prove superiority over well-supported conventional care. | Best as short-term rescue under guidance. AAD / RCT |
| “Food elimination fixes eczema.” | DOESN'T routinely | AAD says removing foods rarely stops AD and broad elimination can harm growth/nutrition in children. | Test only when clinical pattern fits. AAD |
| “Vitamin D works for eczema.” | MIXED | Meta-analyses conflict: modest benefit in 2024, no general effect in 2023. | Deficiency correction is a separate nutritional indication; a greater eczema response in deficient people was not established by the pooled evidence. 2024 review / 2023 review |
| “Probiotics treat eczema.” | DOESN'T routinely | Cochrane found little or no difference in symptoms. | Strain-specific adult evidence is preliminary; high-risk patients need safety review. Cochrane |
| “Evening primrose oil cures eczema.” | DOESN'T | Cochrane found no advantage over placebo. | Can still cause GI effects and bleeding cautions. Cochrane |
Text version of this infographic
The strongest evidence tier is daily moisturizers plus appropriate topical anti-inflammatory medicines. Bathing and clinician-supervised wet wraps have conditional guideline support. Vitamin D and omega-3 have uncertain or preliminary supplement evidence and should not be assigned the same treatment tier. Weak routine-treatment evidence applies to probiotics. Negative evidence applies to evening primrose oil and borage oil. Eczema cure claims should be avoided.
Selected risks and side effects
| Treatment / ingredient | Reported symptoms / frequency limits | Uncommon or serious risks | Higher-risk situations | Source |
|---|---|---|---|---|
| Moisturizers | Stinging, burning, itch, redness, folliculitis; urea/lactic acid may sting active eczema. | Individual ingredients can cause irritant or allergic reactions; the review does not establish rates for every preservative, botanical or lanolin formulation. Emollient residue on fabric creates a fire hazard. NICE | Open cracks, infected skin, known contact allergy, products with fragrance/essential oils. | Cochrane |
| Topical corticosteroids | Itching, folliculitis, acneiform eruption, pigment change, skin thinning with misuse. | Atrophy, striae, telangiectasia, delayed wound healing, secondary infection; rare HPA-axis suppression, Cushing syndrome, hyperglycemia, glaucoma with high exposure. | High potency, long duration, large areas, thin skin, occlusion/wet wraps, children, multiple steroid products. | NCBI Bookshelf |
| Topical calcineurin inhibitors | Transient burning, stinging, pain, pruritus at application site. | FDA boxed malignancy warnings remain. The 2023 AAD guideline discusses some observational lymphoma signals with low absolute risk and uncertain clinical significance; the 2018 review is not a guarantee of no long-term risk. 2023 guideline | Weakened immune system, active infection, use without diagnosis, extensive off-label use. | Topical nonsteroid review |
| Topical PDE-4 inhibitors | Application-site pain, burning, stinging. | The cited 2018 crisaborole review did not identify serious treatment-related events in its selected trials, with follow-up through one year. This does not clear every newer PDE-4 product or all later long-term risks. | Severe burning, open skin, allergy to vehicle ingredients. | Topical nonsteroid review |
| Wet wrap therapy | Reported discomfort or local irritation; the cited small adrenal study does not quantify common symptoms for children. | Increased steroid absorption and infection concern. A small uncontrolled adult inpatient cohort found adrenal suppression after short-course steroid wraps; many had prior steroid exposure or low baseline cortisol, so this is not a pediatric incidence estimate. | Infants/young children, high-potency steroids, large body surface area, suspected infection, long duration. | Wet-wrap adrenal study / NCBI Bookshelf |
| Topical ruxolitinib | Label-reported reactions include local reactions, folliculitis and infections; frequency varies by age and indication. | Boxed warnings address serious infection, mortality, malignancy, major cardiovascular events and thrombosis. Much of the comparative class-warning evidence comes from oral JAK treatment in older high-risk rheumatoid-arthritis patients, not an equivalent measured risk in topical eczema users. | Screen individual risks; use within area/quantity limits, without occlusion. Pregnancy data are insufficient; the label advises no breastfeeding during use or for four weeks after stopping. | June 2026 FDA label |
| Vitamin D | Usually none at appropriate nutritional doses; excess can cause nausea, vomiting, weakness, dehydration, excessive thirst, urination, appetite loss. | Hypercalcemia, hypercalciuria, kidney stones, renal failure, soft-tissue calcification, arrhythmias, death in extreme toxicity. | High-dose supplement stacking, kidney disease, hyperparathyroidism, thiazide diuretics, high calcium intake. | NIH ODS |
| Omega-3 EPA/DHA | Bad breath, unpleasant taste, reflux/heartburn, nausea, GI discomfort, diarrhea, headache, fishy sweat. | High doses can prolong bleeding time; 4 g/day trials in high-risk cardiovascular groups showed slightly higher atrial fibrillation risk. | Discuss high doses, warfarin monitoring, atrial-fibrillation risk and exact formulation/allergy history. Most trials did not find clinically significant bleeding; neither all antiplatelets nor surgery alone is a proven blanket contraindication. | NIH ODS |
| Probiotics | GI symptoms have been reported; reporting is incomplete and rates differ by product, strain and population. | Rare serious or fatal infections in premature infants or severely ill/immunocompromised people; possible harmful substance production or antibiotic-resistance gene transfer. | Premature infants, severe illness and immunocompromise warrant clinician assessment; safety findings from generally healthy trial participants do not establish safety in these groups. | NCCIH |
| Evening primrose / borage oil | Headache, abdominal pain, nausea, upset stomach, diarrhea. | Long-term safety is uncertain. The Cochrane review notes a possible warfarin concern; it does not establish clinical bleeding risk with every anticoagulant or a product-wide borage contamination rate. | Review pregnancy/breastfeeding, childhood use and medicines individually. The Cochrane review specifically rejects the historical EPO–seizure warning as spurious. | Cochrane / NCCIH |
Selected interactions and precautions
| Treatment / ingredient | Medicine, exposure or host precaution | Mechanism / concern | Severity | Action |
|---|---|---|---|---|
| Topical corticosteroids | Wet wraps/occlusion; other steroid medicines; thin-skin sites; large-area use. | Occlusion and inflammation increase absorption; total steroid exposure raises systemic-risk probability. | Monitor | Use the lowest effective potency and duration; avoid unsupervised occlusion. NCBI Bookshelf |
| Topical calcineurin inhibitors | Immunocompromised state, active infection or occlusive dressings in children. | Eligibility and infection review; NICE advises specialist advice before occluding these medicines in children. | Use caution | Use only within the product’s age/eligibility rules and clinician plan. Review / NICE |
| Wet wraps | Topical corticosteroids; infected skin; large body areas. | Occlusion increases drug absorption and moisture can macerate infected skin. | Avoid unsupervised | Use short-term with clinician guidance. NCBI Bookshelf |
| Vitamin D | Thiazide diuretics. | Reduced urinary calcium excretion plus vitamin D can lead to hypercalcemia, especially with kidney impairment or hyperparathyroidism. | Use caution | Clinician monitoring of calcium and 25(OH)D. NIH ODS |
| Vitamin D | Orlistat. | Reduced absorption of fat-soluble vitamin D. | Monitor | Review nutritional status and supplementation with a clinician; the cited fact sheet does not establish a universal dose-separation interval. NIH ODS |
| Vitamin D | Systemic corticosteroids such as prednisone. | Reduced calcium absorption and impaired vitamin D metabolism. | Monitor | Discuss bone/mineral plan if using repeated or chronic systemic steroids. NIH ODS |
| Vitamin D | Atorvastatin, lovastatin, simvastatin. | High vitamin D intake may reduce potency through shared metabolism. | Monitor | Avoid high-dose self-supplementation. NIH ODS |
| Omega-3 EPA/DHA | Warfarin; review other antithrombotics individually. | High doses may lengthen bleeding time, but most studies did not find clinically significant bleeding or a material warfarin-anticoagulation effect. | Monitor | Discuss dose and medicines; warfarin users may need INR monitoring. NIH ODS |
| Omega-3 EPA/DHA | Atrial fibrillation history or high cardiovascular-risk treatment plans. | Large 4 g/day trials found slightly increased atrial fibrillation risk in high-risk groups. | Use caution | Do not start high-dose EPA/DHA without medical oversight. NIH ODS |
| Probiotics | Premature infancy, severe illness or immunocompromise. | Rare bloodstream/fungal/bacterial infection risk from live microbes. | Avoid unless supervised | Use only with clinician approval in high-risk groups. NCCIH |
| Evening primrose oil | Warfarin; other medicines require individual review. | Possible bleeding effect; Cochrane notes warfarin caution. | Use caution | Discuss the possible warfarin concern; obtain product-specific advice rather than using a universal perioperative stopping rule. Cochrane |
| Topical ruxolitinib | Therapeutic biologics, other JAK inhibitors, potent immunosuppressants, strong CYP3A4 inhibitors or occlusive dressings. | Combination immune suppression and increased systemic exposure are safety concerns; topical interaction studies have not been conducted. | Product-specific limits | Follow the label: specified combinations are not recommended, strong CYP3A4 inhibitors should be avoided, and occlusive dressings should not be used. FDA label |
Who should avoid or seek medical care first
Seek prompt medical care for eczema with fever, rapidly spreading redness, severe pain, pus, yellow crusting, eye involvement, widespread blistering, or clusters of painful punched-out blisters that could represent eczema herpeticum. AAD notes germs can enter a weakened atopic dermatitis barrier and infection can result, while NICE recommends same-day specialist assessment for suspected eczema herpeticum in children. Painful spreading or eye-area blistering needs urgent assessment, rather than waiting for an ordinary flare appointment (AAD causes page, Atopic dermatitis review; NICE).
People who should not self-manage with supplements or occlusion include infants with severe disease, premature infants, immunocompromised people, people on anticoagulants, people with kidney disease or hypercalcemia risk, people with extensive eczema, and anyone using high-potency topical steroids over large areas. The relevant concern differs: live-probiotic infection risk in vulnerable hosts, vitamin D toxicity in susceptible people, high-dose omega-3/medicine review, or increased steroid absorption under occlusion. This does not mean every listed treatment is contraindicated in every group (NCCIH probiotics, NIH ODS vitamin D, NIH ODS omega-3, NCBI Bookshelf topical corticosteroids).
Text version of this infographic
- Discuss whether vitamin D replacement is clinically indicated; routine testing or a better eczema response in deficient people is not established for everyone.
- Because probiotics are live microbes, use extra caution in premature infants, severely ill people, and immunocompromised people.
- Review high-dose omega-3 and evening primrose oil with a clinician when using warfarin; assess other medicines or procedures individually rather than assuming a blanket bleeding contraindication.
- Avoid “eczema cure” supplement claims.
- Supplements should not replace moisturizers, trigger management, or prescribed flare medicines.
Evidence, funding, and conflict review
Research funding at a glance
7 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | Disclosures and remaining limits | Credibility rank | Money trail / conflict note | Why it may still be reliable |
|---|---|---|---|---|
| Cochrane emollients review | Review disclosures read; underlying trial ties vary | Strong, with trial-funding caveat. | Oak Foundation/Parker Institute and NIHR support were listed; review authors declared no interests. A protocol referee disclosed company honoraria. Of 77 trials, 46 reported funding, mostly industry; some also had manufacturer-employed investigators. Original review | Transparent methods and explicit risk-of-bias reporting reduce, but do not remove, product-funding distortion risk. |
| AAD atopic dermatitis guideline | Internal AAD funding; workgroup relationships require separate assessment | Strong for clinical recommendations. | The 2023 adult guideline reported internal AAD funding, prohibited direct pharmaceutical-production funding, and recusal procedures. Members disclosed consulting, research, honoraria and some company stock/options. Original 2023 manuscript. The 2026 pediatric treatment and prevention publisher records also report internal AAD funding; complete 2026 member declarations were not recovered. | GRADE methods and declared conflict management support appraisal; they do not eliminate potential influence, and many treatment trials have short follow-up. |
| 2024 vitamin D meta-analysis | Partly conflicted. | Moderate. | No external funding, but two authors disclosed multiple pharma speaker/advisory/research relationships. | Effect estimate is transparent; conflicts argue for conservative interpretation rather than dismissal. |
| EPA pediatric RCT | No specific grant or financial conflicts declared; product-supply terms unreported | Moderate. | Epastigel/Pars Pharmed capsules and paraffin placebo were identified; the paper did not report purchase/donation terms. Authors declared no specific grant and no financial interests/conflicts. | Randomized blinded design supports signal, but sample size and duration were small. |
| Pediatric multi-ingredient blend trial | Company grant and product supply disclosed | Preliminary adjunct evidence | 4U Pharma GmbH funded the trial (grant 01-380/1-21) and supplied active/placebo products; authors declared no conflicts and no sponsor role. Exact cash/material terms were not reported. | The trial tested a blend of EPA, DHA, GLA and vitamin D3 alongside usual care; it cannot isolate a fish-oil effect. |
| Cochrane probiotics review | Review author/company ties disclosed; underlying trial ties vary | Strong for “not routine treatment.” | Institutional/NIHR support was listed. Boyle disclosed Danone and Dairy Goat Co-operative work; Tang disclosed nutrition-company ties, Prota employment/share options and a probiotic-allergy patent interest. Ten trials had supplier funding and four did not declare funding. Original review | Systematic methods and patient-rated outcomes are useful, but a null result does not prove independence or absence of sponsor influence. |
| NCCIH probiotic safety page | Public NIH guidance; page-specific financial chain not fully stated | Strong for safety cautions. | The page describes NCCIH research and states product mentions are not endorsements; complete page-author declarations and every underlying-study financial chain were not supplied. | Useful patient guidance distinguishing products, host risks and incomplete safety reporting; it does not establish equal safety for every strain. |
Frequently Asked Questions
What is an evidence-based approach to an eczema flare?
For atopic dermatitis, a practical guideline-based approach is to moisturize liberally, remove obvious irritants, and use the prescribed topical anti-inflammatory early rather than waiting until the flare is severe. AAD strongly recommends moisturizers and topical anti-inflammatory medicines, while wet wraps are a conditional short-term option for selected flares (AAD guideline).
Should eczema skin be bathed every day?
AAD conditionally supports bathing, but the reviewed guideline does not establish one optimal daily frequency, temperature or duration. Use a tolerable, gentle washing plan and prompt moisturizer; for children under 12, NICE advises emollient soap substitutes and does not recommend separately marketed emollient bath additives (AAD guideline; NICE).
Are topical steroids dangerous for eczema?
Topical corticosteroids are evidence-based flare medicines, but risk rises with high potency, prolonged use, large treated areas, thin skin, and occlusion. Known side effects include skin thinning, striae, telangiectasia, acneiform eruptions, delayed wound healing, and rare systemic effects such as adrenal suppression when exposure is high (NCBI Bookshelf).
Do probiotics help eczema?
For established eczema, not reliably. Cochrane reviewed 39 randomized trials with 2,599 participants and concluded that currently available probiotics probably make little or no difference to patient-rated eczema symptoms (Cochrane probiotics review).
Does vitamin D help eczema?
Vitamin D is mixed: a 2024 meta-analysis found a modest severity reduction across 11 RCTs, while another meta-analysis found no general effect and strong subgroup uncertainty. Correcting clinically indicated deficiency is a separate nutritional issue; these pooled studies did not establish a reliably greater eczema response in deficient people. Excess vitamin D can cause hypercalcemia and kidney complications (2024 meta-analysis, NIH ODS vitamin D).
Does fish oil or omega-3 help eczema?
Omega-3 evidence is promising but not settled. A small four-week adjunct EPA trial in children reported improved SCORAD; authors declared no specific grant or financial conflicts, but capsule purchase/donation terms were not reported. The older Cochrane review found no convincing evidence for dietary supplements as routine eczema treatment and called the fish-oil evidence modest and small-study based (EPA RCT, Cochrane dietary supplements review).
Does evening primrose oil help eczema?
The cited 2013 review did not find a reliable eczema benefit. Cochrane reviewed 27 studies with 1,596 participants and found no statistically significant advantage for evening primrose oil or borage oil over placebo (Cochrane evening primrose/borage review).
Can food elimination cure eczema?
Food allergy can coexist with eczema, but broad food elimination rarely stops atopic dermatitis and can harm children through poor growth, nutrient deficiency, or protein malnutrition. AAD recommends food allergy testing mainly when moderate-to-severe eczema remains uncontrolled despite good skin care and medication or when an immediate reaction follows a specific food (AAD food guidance).
Sources
- American Academy of Dermatology. Atopic dermatitis clinical guideline. https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis
- Cochrane. Emollients and moisturisers for eczema. https://www.cochrane.org/evidence/CD012119_emollients-and-moisturisers-eczema
- Cochrane. Probiotics for treating eczema. https://www.cochrane.org/evidence/CD006135_probiotics-treating-eczema
- Cochrane. Oral evening primrose oil and borage oil for eczema. https://www.cochrane.org/evidence/CD004416_oral-evening-primrose-oil-and-borage-oil-eczema
- Cochrane. Dietary supplements for established atopic eczema in adults and children. https://www.cochrane.org/evidence/CD005205_dietary-supplements-established-atopic-eczema-adults-and-children
- NICE. Atopic eczema in under 12s: diagnosis and management. https://www.nice.org.uk/guidance/cg57/chapter/Recommendations
- AAD. Eczema Resource Center. https://www.aad.org/public/diseases/eczema
- AAD. Atopic dermatitis causes. https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/causes
- AAD. Childhood eczema triggers. https://www.aad.org/public/diseases/eczema/childhood/triggers
- AAD. Can food fix eczema? https://www.aad.org/public/diseases/eczema/childhood/treating/food-fix
- Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. https://pmc.ncbi.nlm.nih.gov/articles/PMC5216178/
- Hindley D, et al. A randomised study of wet wraps versus conventional treatment for atopic eczema. https://pmc.ncbi.nlm.nih.gov/articles/PMC2082699/
- Nielsen AY, et al. Vitamin D supplementation for treating atopic dermatitis. https://pmc.ncbi.nlm.nih.gov/articles/PMC11644640/
- Park JS, et al. Effect of vitamin D on treatment of atopic dermatitis. https://pmc.ncbi.nlm.nih.gov/articles/PMC10079516/
- Mirrahimi B, et al. Evaluating EPA in children with atopic dermatitis. https://pmc.ncbi.nlm.nih.gov/articles/PMC9901318/
- NIH ODS. Omega-3 fatty acids fact sheet. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
- NIH ODS. Vitamin D fact sheet. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
- NCCIH. Probiotics: usefulness and safety. https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety
- NCCIH. Evening primrose oil: usefulness and safety. https://www.nccih.nih.gov/health/evening-primrose-oil
- Gabros S, Nessel TA, Zito PM. Topical corticosteroids. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK532940/
- Papier A, Strowd LC. Atopic dermatitis: a review of topical nonsteroid therapy. https://pmc.ncbi.nlm.nih.gov/articles/PMC5886549/
- van Zuuren EJ, et al. Emollients and moisturisers for eczema: full original Cochrane review (2017). Original source
- Makrgeorgou A, et al. Probiotics for treating eczema: full original Cochrane review (2018). Original source
- Bamford JTM, et al. Oral evening primrose oil and borage oil for eczema: full original Cochrane review (2013). Original source
- Pediatric EPA/DHA/GLA/vitamin D3 blend trial (2024). Original source
- Topical corticosteroid wet-wrap treatment and adrenal suppression: adult cohort (2021). Original source
- Kapur S, Watson W, Carr S. Atopic dermatitis review (2018). Its supplement publication had industry funding and author relationships; this historical review is used for diagnosis/infection context, not current drug selection. Original source
- AAD adult topical-treatment guideline: recovered original accepted manuscript (2023). Original source
- AAD pediatric treatment guideline: original publisher abstract and funding record (2026). Original source
- AAD pediatric primary-prevention guideline: original publisher abstract and funding record (2026). Original source
- FDA. Opzelura/ruxolitinib cream prescribing information, revised June 2026. Original source
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.